Communiqués Ribomic Inc.

Actions

4591

JP3974850004

Recherche biotechnologique et médicale

Marché Fermé - Japan Exchange 08:30:00 10/09/2026			Varia. 5j.	Varia. 1 janv.
82,00 ^JPY	-1,20%		-1,20%	+5,13%

24/08	Ribomic annonce la finalisation du réseau de centres pour l'essai clinique de phase 3 de l'umedaptanib pegol dans l'achondroplasie	CI
13/08	Ribomic Inc. publie ses prévisions de résultats non consolidés pour l'exercice clos le 31 mars 2027	CI

Communiqués

07/10/25	RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older	BU
05/11/24	RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort	BU
03/08/24	RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study	BU
05/12/23	RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)	BU
29/07/22	RIBOMIC : Announces Issuance of US Patent for its RBM-010, Novel Drug Candidate for Osteoarthritis	PU
10/06/22	Ribomic : 【Delayed】RIBOMIC Announces Publication Highlighting Novel Approach to Generate Aptamer using AI in the Nature Computational Science	PU
19/04/22	RIBOMIC : Announces Completion of IND submission for an Observational Study for Continuous Phase 2 Trial of RBM-007 for Treatment of Achondroplasia	PU
23/03/22	RIBOMIC : Provides Update on RBM-007 Program in Wet Age-Related Macular Degeneration	PU
11/01/22	RIBOMIC : Announces Presentation Materials of the 40th Annual J.P. Morgan Healthcare Conference	PU
28/12/21	RIBOMIC : Announces Preliminary Topline Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration	PU
23/12/21	RIBOMIC : Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference	PU
15/11/21	RIBOMIC Announces RBM-007 Phase 1 Clinical Trial Results for Achondroplasia	BU
15/11/21	RIBOMIC : Announces RBM-007 Phase 1 Clinical Trial Results for Achondroplasia	PU
09/11/21	Summary of Non-Consolidated Financial Results for the Six Months Ended September 30 2021(Based on Japanese GAAP)	PU
30/09/21	RIBOMIC : Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration at the Retina Society 2021 Meeting	BU
30/09/21	RIBOMIC : Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet AMD at the Retina Society 2021 Meeting	PU
30/08/21	RIBOMIC : Completes Patient Enrollment of its US Phase 2 Open-Label Extension Clinical Trial of RBM-007 for wet AMD (RAMEN Study)	PU
05/08/21	RIBOMIC : Completes Patient Enrollment of its US Phase 2 Clinical Trial of RBM-007 for Wet Age-Related Macular Degeneration (TOFU Study)	PU
12/07/21	RIBOMIC : Announces First Patient Dosed in an Investigator Sponsored Trial of RBM-007 in treatment naive wet AMD Patients	PU
28/05/21	RIBOMIC : Announces Termination of MTA with The Pritzker Neuropsychiatric Disorders Research Consortium	PU
25/05/21	Ribomic : Summary of Non-Consolidated Financial Results for the Year Ended March 31, 2021 (Based on Japanese GAAP)	PU
21/05/21	RIBOMIC : Announces Completion of its Phase I Trial of RBM-007 for the Treatment of Achondroplasia	PU
21/05/21	RIBOMIC : Announces Publication of a Research Paper on an Aptamer Creation Platform Technology for Membrane Receptor GPCR	PU
21/05/21	RIBOMIC : Announces Publication of Research Paper on Aptamer Drug Discovery for Achondroplasia	PU
24/02/21	Ribomic : Summary of Non-Consolidated Financial Results for the Nine Months Ended December 31, 2020 (Based on Japanese GAAP)	PU